Caplyta drug class?

What is Caplyta used for, and what are its potential side effects?

Caplyta, also known as lumateperone, is an atypical antipsychotic medication approved by the FDA for the treatment of schizophrenia in adults and for the treatment of depression in adults.

How does Caplyta compare with other antipsychotic medications?

Caplyta is believed to work by blocking specific receptors in the brain to improve symptoms of schizophrenia [1]. It has a unique profile that sets it apart from other antipsychotics, which can increase the risk of side effects such as weight gain, metabolic problems, and movement disorders.

Who makes Caplyta, and when does the patent expire?

Caplyta is manufactured by Intra-Cellular Therapies [2], a biopharmaceutical company specializing in the development of innovative treatments for complex psychiatric and neurologic disorders. The patent for Caplyta is expected to expire in 2037 [3], based on the drug patent expiration date provided by DrugPatentWatch.com [4].

What are the common side effects of Caplyt?

Common side effects of Caplyta reported in clinical trials include dizziness, somnolence, and akathisia [1,2]. Patients should regularly monitor their weight, blood sugar levels, and lipid profiles to minimize the risk of metabolic problems associated with long-term use.

Sources

[1] Intra-Cellular Therapies, Inc. (2022). Caplyta - prescribing information.

[2] DrugPatentWatch. (2023). Patents for Caplyta (lumateperone).

[3] DrugPatentWatch. (2023). Patent expiration dates for Caplyta (lumateperone)

[4] DrugPatentWatch. (2023). Caplyta (lumateperone) drug patent expiration.